Recursion Pharmaceuticals: 2026 priorities and analyst outlook

What happened: On May 14, 2026, Morgan Stanley raised its price target on Recursion Pharmaceuticals (RXRX) to $5.50, an 11.1% increase from the previous target of $5. This upgrade follows Recursion's announcement on May 6, 2026, outlining its 2026 priorities, which included advancing its pipeline and expanding its platform. JPMorgan, however, trimmed its price target on the same day, from $11 to $10, while maintaining an Overweight rating.

Market impact: The pharmaceutical sector is affected, with RXRX experiencing a valuation repricing. The price target increases suggest analysts' growing confidence in Recursion's pipeline and platform expansion, driving potential investment in the stock. The 100% upside potential based on the 1-year median price target of $7 indicates a moderately bullish consensus sentiment.

What to watch next: Recursion's upcoming catalysts include its second-quarter 2026 earnings report, expected on August 15, 2026, which will provide insights into its progress against its 2026 priorities. Additionally, investors should monitor the U.S. Food and Drug Administration's (FDA) decisions on Recursion's pipeline, particularly the IND clearance for its lead program, RPT193, expected in the second half of 2026. Lastly, the stock's technical levels, such as support and resistance, will help gauge investor sentiment and potential price movements.